A
16.13
0.25 (1.57%)
| 前收盘价格 | 15.88 |
| 收盘价格 | 15.81 |
| 成交量 | 2,735 |
| 平均成交量 (3个月) | 1,779 |
| 市值 | 1,582,825,472 |
| 52周波幅 | |
| 利润日期 | 7 Aug 2025 |
| 营业毛利率 | -26.41% |
| 营业利益率 (TTM) | 70.24% |
| 稀释每股收益 (EPS TTM) | -1.08 |
| 季度收入增长率 (YOY) | -29.60% |
| 总债务/股东权益 (D/E MRQ) | 108.23% |
| 流动比率 (MRQ) | 5.15 |
| 营业现金流 (OCF TTM) | 61.15 M |
| 杠杆自由现金流 (LFCF TTM) | -6.46 M |
| 资产报酬率 (ROA TTM) | -5.86% |
| 股东权益报酬率 (ROE TTM) | -26.22% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (GB) | 混合的 | 混合的 |
| Biotechnology (全球的) | 混合的 | 看跌 | |
| 股票 | ARROWHEAD PHARMACEUTICALS INC A | - | - |
AIStockmoo 评分
1.1
| 分析师共识 | 0.0 |
| 内部交易活动 | NA |
| 价格波动 | -2.0 |
| 技术平均移动指标 | 2.5 |
| 技术振荡指标 | 4.0 |
| 平均 | 1.13 |
相关股票
| 股票 | 市值 | DY | P/E（TTM） | P/B |
|---|---|---|---|---|
| ARROWHEAD PHARMACEUTICALS INC A | 2 B | - | - | - |
| RELIEF THERAPEUTICS HOLDING SA | 2 B | - | - | - |
| IDORSIA LTD IDORSIA N ORD SHS | 1 B | - | - | - |
| OXFORD NANOPORE TECHNOLOGIES PL | 1 B | - | - | 2.97 |
| BASILEA PHARMACEUTICA AG BASILE | 560 M | - | - | - |
| IOVANCE BIOTHERAPEUTICS INC IOV | 401 M | - | - | - |
|
Arrowhead Pharmaceuticals Inc is an American biotechnology company. Its main target is the development of medicine to treat diseases with a genetic origin, characterized by the overproduction of one or more proteins. Its medical solutions are aimed at the genes that trigger the diseases. Its portfolio includes drugs targeting hepatitis B, Alpha-1 Antitrypsin Deficiency, thrombosis and angioedema, clear-cell and renal cell carcinoma, and cardiovascular disease. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Value |
| 内部持股比例 | 13.02% |
| 机构持股比例 | 77.19% |
该时间范围内无数据。
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合